Deintensification of treatment goals is recommended to reduce the risk of hypoglycemia if it can be achieved within the individualized A1C target
To view a copy of this licence, visit About this article Cite this article Krishna, S., Dungan, K.M., Shah, R
Zinc supplementation (commonly used in Wilson disease maintenance therapy) induces intestinal metallothionein, which sequesters copper in enterocytes and reduces absorption [10]
Vitamin D Toxicity Although vitamin D toxicity is rare, too much can cause high levels of calcium concentrations or hypercalcemia
[1] [2] As of 2024, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed medicine in the UK